Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma

Grunenberg, A; Kaiser, LM; Woelfle, S; Schmelzle, B; Viardot, A; Moller, P; Barth, TFE; Muche, R; Dreyhaupt, J; Buske, C

Buske, C (corresponding author), Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.

FUTURE ONCOLOGY, 2020; 16 (13): 817